Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, 1090 Brussels, Belgium.
Anticancer Res. 2010 Dec;30(12):5185-8.
Pemetrexed-induced eyelid edema is a rare side-effect of pemetrexed treatment.
Retrospective analysis of the incidence and severity of eyelid edema was conducted in patients treated with pemetrexed in a single institution.
Eighty-six patients received pemetrexed-containing chemotherapy either as a single agent (45 patients) or in combination with cis- or carboplatin (41 patients). Two patients (2.3%) with stage IV non-small cell lung cancer (NSCLC) presented the edema typically localized in the lower eyelid after first-line treatment with carboplatin-pemetrexed. The edema remained identical in both patients during treatment and regressed in one patient in whom treatment was withdrawn. No other localizations of edema were observed in these patients.
Pemetrexed-induced eyelid edema may be more frequent than originally reported. The physiopathological mechanism and, as a consequence, the treatment and/or prevention of this apparently benign side-effect remains unknown.
培美曲塞引起的眼睑水肿是培美曲塞治疗的罕见副作用。
在一家机构中,对接受培美曲塞治疗的患者中眼睑水肿的发生率和严重程度进行回顾性分析。
86 例患者接受培美曲塞为单一药物(45 例)或联合顺铂或卡铂(41 例)治疗。2 例 IV 期非小细胞肺癌(NSCLC)患者在一线治疗中使用卡铂-培美曲塞后出现典型的下眼睑水肿。在这 2 例患者中,在治疗期间水肿保持不变,1 例患者停止治疗后水肿消退。这些患者未观察到其他部位的水肿。
培美曲塞引起的眼睑水肿可能比最初报道的更为常见。其病理生理机制,以及因此而导致的这种明显良性副作用的治疗和/或预防仍不清楚。